What are the advantages of Sotorasib compared with chemotherapy?

Sotorasib is a targeted drug that specifically targets KRAS G12C mutations and is mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying such mutations. Compared with traditional chemotherapy, sotoracib shows obvious advantages in many aspects, especially in terms of efficacy, side effect management and personalized treatment.

First of all, from the perspective of therapeutic effect, sotoraxib is highly selective against the KRAS G12C mutation target. In clinical studies, its objective response rate (ORR) is about 37%, and its disease control rate (DCR) exceeds 80%. Some patients can achieve progression-free survival of more than half a year or even one year. In comparison, traditional chemotherapy has a lower response rate in patients with such genetic mutations, and the duration of efficacy is limited. Therefore, sotorasiib provides a more precise and sustainable treatment option for this type of "refractory" mutation population.

Secondly, in terms of side effects, sotoracib is milder than chemotherapy. Common side effects of chemotherapy include hair loss, leukopenia, severe nausea and vomiting, and systemic immunosuppression. The main side effects of sotoraxib are mostly mild to moderate, such as diarrhea, fatigue, elevated liver enzymes, etc., which can usually be controlled through symptomatic treatment and do not affect the patient's quality of daily life. Better tolerability makes it easier for patients to adhere to treatment and also provides the possibility for long-term medication.

In addition, sotoracib represents the personalized medical concept of targeted therapy. After the KRAS G12C mutation is confirmed through genetic testing, "tailored" precise medication can be achieved. This method not only improves the treatment efficiency, but also avoids the waste of resources and patient pain caused by blind medication. Chemotherapy is a non-specific killing method, which also has strong damage to normal cells, has serious side effects, and the efficacy varies from person to person.

To sum up, sotoracib is superior to traditional chemotherapy in terms of more precise efficacy, easier control of side effects, and more in line with modern personalized medicine trends. It is especially suitable for patients with confirmed KRAS G12C mutationsNSCLC. With the advancement of targeted drug technology, sotoraxib is gradually replacing traditional chemotherapy and becoming an important treatment option for such patients.

Reference materials:https://www.lumakras.com/